Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 16/20 | 0.53 |
| ▸ | BRD4 | O60885 | 13/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.53 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | PDXK | O00764 | 1/20 | 0.46 |
| ▸ | WEE1 | P30291 | 1/20 | 0.46 |
| ▸ | NEK3 | P51956 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.46 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30501315 | 1.00 | PLK1 (0.53) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL25031474 | 0.94 | PLK1 (0.48) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL30501293 | 0.94 | PLK1 (0.54) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL25031288 | 0.94 | PLK1 (0.54) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL25034774 | 0.92 | PLK1 (0.65) | PLK1BRD4BRDTPLK3RAD52 | |
| SCHEMBL30501287 | 0.90 | PLK1 (0.55) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL25029388 | 0.90 | PLK1 (0.55) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL25029381 | 0.89 | PLK1 (0.49) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL25034982 | 0.87 | PLK1 (0.52) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL31405225 | 0.87 | BRD4 (0.57) | PLK1BRD4BRDTDCLK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| WO-2023018236-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | PLK1 1/4885BRD4 903/4885BRDT 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.